Arpida Reports Outcome of Drug Interaction Trial

Swiss drugmaker Arpida reported results of a Phase I trial investigating the possible interaction between intravenous iclaprim and warfarin.

Warfarin is widely used for the prophylaxis of thrombosis and embolism, and its dosing needs to be well controlled.

The German study enrolled 24 healthy volunteers. Dosing of warfarin with and without pre- and co-administration of iclaprim (1.6 mg/kg infused over an hour) was investigated.

Administration of iclaprim was assessed to be safe for clinical applications and had no significant effect on the pharmakonetics and pharmacodynamics of warfarin, Arpida said.